Get To Know The New ASEF Podcast Guests [Episode #33]
In this special live episode of the ASEF Podcast, recorded at Dragon Days in Celje, ASEF Junior Fellow Frenk Dragar hosted two new guests: Michael Stucky, a partner at Serpentine Ventures, visiting from Zurich, Switzerland; and Jure Vindišar, Head of Technology Transfer at the National Institute of Biology in Slovenia.
We delved into the concept of technology transfer, which is all about creating real-world impact from cutting-edge research. This encompasses things like university spin-outs and licensing intellectual property for the purpose of bringing scientific innovations to the market. Tune in to hear inspiring stories of deep-tech entrepreneurship from Slovenia and Switzerland, the importance of innovation clusters, insights from Mario Draghi’s recent report on the EU’s competitiveness, and a broader perspective on what it takes to build a thriving technology transfer ecosystem.
ABOUT OUR GUESTS
Jure Vindišar is the Head of Technology Transfer Office at the National Institute of Biology. With over 15 years of experience in supporting research and innovation in industrial and public research sectors, his focus is on the research impact and the development of excellent innovation-driven research environments at NIB and at the national level. He supports researchers in identifying and developing impact driven research activities, building partnerships with industry (research collaboration agreements, licencing agreements, spin outs), organizing workshops on IP, VC financing and commercialisation and managing the institute’s IP portfolio.
Jure Vindišar is representing NIB at the Slovenian TTO Consortium and is a member of the Annual Conference Programme Committee at EARMA (European Association of Research Managers and Administrators).
Michael Stucky is a partner at Serpentine Ventures as well as a coach and mentor of young entrepreneurs and spin-off companies in Switzerland. In addition, Michael is the co-founder and chairman of Auxivo AG, and chairman of FenX AG, both ETHZ spin-off companies. Before that, he was the founding COO of Wyss Zurich, an accelerator focused on the translation of innovative medical therapies and robotics technologies. Prior to joining the ETHZ, Michael was CFO and co-founder of GlycoVaxyn, a Swiss biotech start-up (sold to GSK).
Earlier in his career, he had spent 10 years at the Swiss bank Lombard Odier, both in Switzerland and North America, where he worked as a financial analyst and fund manager before ultimately running the bank’s Canadian operations. Michael also worked for UBS’s investment banking division on equity capital market transactions. He is also a co-founder of several startups in both Switzerland and Silicon Valley. He holds a master’s in Management from the Stanford Graduate School of Business, California, and an MBA in Finance from the University of Zurich, Switzerland.